Drugs / CD19 CARvac T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04156243 | Feb 2018 → Feb 2020 | B-cell non-Hodgkin lymphoma, lymphoid leukemia | iCell Gene Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 CARvac T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04156243 ↗ |
| Modality | Cell therapy | “CD19 CARvac T cells transduced with a lentiviral vector to express” NCT04156243 ↗ |
| Route | Intravenous | “by IV injection” NCT04156243 ↗ |
| Target | CD19 | “Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy.” PMID 32840736 ↗ Dec 2020 |